TriangleRuxolitinib (NCT05592015)
Ruxolitinib trial for T-Cell Large Granular Lymphocyte Leukemia (NCT05592015). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with large granular lymphocytic leukemia needing treatment for anemia or low neutrophils. Untreated disease or disease after failed treatment is allowed. Selected natural-killer-cell cases also qualify.
The idea: test ruxolitinib tablets twice daily in four-week cycles. Ruxolitinib blocks JAK enzymes involved in growth and immune signaling. Treatment lasts up to one year, with another year possible for patients who respond. Blood tests track response, and researchers compare results with historical data.
This phase 2 study plans 30 patients. Jonathan Brammer leads three recruiting US sites.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.